Answers are grounded in this paper and cite their sources.
Long-term therapy with dupilumab shows reduced treatment burden and sustained efficacy in CRSwNP, suggesting improved management strategies.
Long-term dupilumab therapy provided durable disease control and excellent safety. Personalized dosing-interval extension maintained efficacy and reduced treatment burden, supporting its potential role in optimizing long-term management of CRSwNP, especially in patients with troublesome side effects.
No takes yet. Share an insight, caveat, or question.
Campion et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: